UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACTOF 1934 For the fiscal year ended December 31, 2024 OR Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0001 MTNB NYSE American For the transition ...

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. “We are thrilled to announce the addition of Keith and Edward to our Board,” stated Jerome D. Jabbour, ...

BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (the “Company”) today announced that the Company entered into a securities purchase agreement (the “Agreement”) with a certain group of investors (the “Investors”), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the “Preferred Stock”) and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share ...

BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of Evelyn D’An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D’An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of A ...

BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Commi ...

BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below certain NYSE American continued listing standards because it failed to hold its annual meeting of stockholders for the fiscal year ending on December 31, 2024, as set forth in Section 704 of the NYSE American Company Guide. The Company intends to hold its annual meeting no later than ...

Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203 Compassionate/Expanded Use Access Program with 6 additional patients under evaluation Additional LNC platform work in inflammation and oncology completed; Company evaluating next steps Conference call begins at 4:30 p.m. Eastern time today BEDMINSTER, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Matinas B ...

Financial Performance - For the six months ended June 30, 2024, the net loss was $11,543, compared to a net loss of $11,573 for the same period in 2023[61]. - No revenue was generated during the three and six months ended June 30, 2024, while $1,096 was generated in contract research revenue during the same periods in 2023[62]. - Total revenues for the six months ended June 30, 2024, were $0, compared to $1,096 in the same period of 2023, primarily due to the absence of contract research revenue[78]. - Cash used in operating activities for the six months ended June 30, 2024, was $(8,875), an increase from $(6,280) in the same period of 2023[81]. - Net cash provided by financing activities for the six months ended June 30, 2024, was $9,242, compared to $(5) in the prior year, driven by proceeds from a registered direct offering[84]. Research and Development Expenses - Total research and development expenses for the three months ended June 30, 2024, were $3,371, a decrease of 5.3% from $3,559 in the same period of 2023[74]. - The total research and development expenses for the six months ended June 30, 2024, were $6,817, compared to $7,530 for the same period in 2023, reflecting a decrease of 9.5%[65]. - Research and Development (R&D) expenses for the six months ended June 30, 2024, were $6,817, a decrease of 9.5% from $7,530 in the same period of 2023[77]. - Research and development expenses are anticipated to increase over time as product candidates move into later stages of clinical development[66]. General and Administrative Expenses - General and administrative expenses for the three months ended June 30, 2024, were $2,468, down from $2,600 in the same period of 2023[67]. - General and Administrative (G&A) expenses for the six months ended June 30, 2024, were $4,925, down 7.3% from $5,311 in the prior year[77]. Future Outlook and Concerns - The company expects to incur additional operating losses for the foreseeable future and has substantial doubt about its ability to continue as a going concern[61]. - The company has incurred operating losses since inception and does not expect to generate product revenue for many years[62]. - The company expects to incur significant expenses and increasing operating losses for the foreseeable future, particularly related to clinical studies and product development[85]. - There is substantial doubt about the company's ability to continue as a going concern beyond the next twelve months without additional funding[86]. - The company anticipates financing its cash needs through a combination of equity offerings, debt financings, and collaborations[87]. Funding and Cash Position - As of June 30, 2024, the company had unrestricted cash, cash equivalents, and marketable debt securities totaling $14,313[78]. - The company raised a total of $166,907 in gross proceeds from equity securities since inception, with net proceeds of $153,445[78]. - The company relies on collaborations and licensing arrangements to fund operations, which may not be available on acceptable terms[61]. - The company plans to advance MAT2203 into the ORALTO trial for the treatment of invasive aspergillosis, aiming to establish a pharmacodynamic bridge for further indications[58].